The end of the public health emergency caused a meaningful decline in the retail COVID market as well as molecular, even as antigen testing has picked up Share on the professional market from competitive molecular systems. Due to these two headwinds on the COVID market, our COVID outlook has come down. In light of these dynamics, we are updating our fiscal 2023 full year guidance as follows: total revenue of 2.88 To $3,080,000,000 compared to our prior guidance of $2,870,000,000 to 3,180,000,000 Breaking this down a little further, we are raising our non respiratory revenue guidance to the high end of our prior guide, While lowering our respiratory guidance, non respiratory revenue is expected to grow 5 to 6.5% on a constant currency basis to 2.27000000000 to 2.31000000000 Up from our prior guidance of 4.5% to 6.5% on a constant currency basis to 2.26000000000 to 2.31000000000 We now have a respiratory revenue guide of $610,000,000 to 775,000,000 including COVID revenue of $300,000,000 to $400,000,000 compared to our prior guide of $610,000,000 to 8.75 $1,000,000 including COVID revenue of $300,000,000 to $500,000,000 And it's interesting to note that in the second half of twenty twenty three, We expect that more than 93% of our COVID revenue forecast is in the professional market.